Hydromethylthionine HBr

• CAT Number: I028976
• CAS Number: 951131-15-0
• Molecular Formula: C16H21Br2N3S
• Molecular Weight: 447.23
• Purity: 98%
• Synonyms: Hydromethylthionine HBr; TRX-0237 HBr; TRX-0237 dihydrobromide; TRX0237; TRX 0237; Leucomethylene Blue dihydrobromide; Leukomethylene Blue dihydrobromide; Reduced methylene Blue dihydrobromide
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: N3,N3,N7,N7-Tetramethyl-10H-phenothiazine-3,7-diamine dihydrobromide
• InChI: InChI=1S/C16H19N3S.2BrH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;;/h5-10,17H,1-4H3;2*1H
• InChIKey: JAUPSVVTGFBHTN-UHFFFAOYSA-N
• SMILES: CN(C)C1=CC(SC2=CC(N(C)C)=CC=C2N3)=C3C=C1.[H]Br.[H]Br

Hydromethylthionine HBr(CAT: I028976), also known as methylthioninium bromide, is a small molecule that functions as a tau aggregation inhibitor, targeting the pathological aggregation of tau proteins in neurodegenerative diseases such as Alzheimer’s disease and frontotemporal dementia. By disrupting tau aggregation, it helps restore normal cellular function and reduce neurotoxicity. Hydromethylthionine HBr is widely studied in neuropharmacology research, where it has demonstrated potential to modify disease progression by targeting a key driver of tauopathies. Its mechanism of action provides insights into therapeutic strategies for treating tau-associated neurodegenerative disorders, contributing to advancements in disease-modifying treatments for dementia.